加味参附颗粒对慢性心力衰竭及心肌能量代谢的研究
|
摘要
目的
通过临床研究观察加味参附颗粒对慢性心力衰竭患者心功能、运动耐力的影响；并通过动物实验观察其对心衰大鼠心肌超微结构及线粒体Na+-K+-ATP酶、Ca2+-ATP酶活性的影响,进而从能量代谢方面探讨加味参附颗粒治疗慢性心力衰竭的可能机制。
方法
本研究包含两部分内容,第一部分是以慢性心力衰竭患者为研究对象。第二部分是以慢性心力衰竭模型大鼠为研究对象。
(一)第一部分(临床研究)
按照随机对照研究原则,将80例符合慢性心力衰竭西医诊断标准(NYHA心功能分级Ⅱ、Ⅲ)并且中医辨证属于“心肾阳(气)虚、血瘀水停证”患者分为治疗组及对照组,对照组选用常规西医药物治疗,治疗组在对照组的基础上加用加味参附颗粒。观察患者治疗前后临床症状、BNP、EF%、E/A.6分钟步行试验的变化。
(二)第二部分(动物实验)
清洁级SD雄性大鼠40只,按照数字表原则分为正常对照组、模型对照组、西药组、加味参附颗粒组A(临床等效量组)和加味参附颗粒组B(2倍临床等效量组),每组8只大鼠。除正常对照组外各组先进行造模处理。造模成功后,各组予相应的干预：正常对照组：给予每日灌服蒸馏水2ml；模型对照组：给予每日灌服蒸馏水2ml；西药组：给予每日灌服5.4mg/kg曲美他嗪片；加味参附颗粒组A：给予每日灌服6.84g生药/kg(等同于临床效量),加味参附颗粒组B：给予每日灌服13.68g生药/kg(等同于2倍临床效量)
疗程4周。观察指标包括：体重、心脏重量、左室重量、心体重量比、左室全心比、动脉压、右心室内压力、心率、左心室内压最大上升和下降速率[Max±dP/dt (mmHg/s)]、心肌线粒体结构、线粒体Na+-K+-ATP酶和Ca2+-ATP酶活性。
结果
(一)第一部分(临床研究)
1.两组心功能NYHA分级疗效比较,治疗组总有效率87.50%,对照组总有效率为70.00%,两组比较,治疗组总有效率高于对照组,且差异有统计学意义(P<0.05)。
2.两组Lee氏心衰记分法疗效比较,治疗组总有效率85.00%,对照组总有效率为67.50%,两组比较,治疗组总有效率高于对照组,且差异有统计学意义(P<0.05)。
3.两组治疗后6MWT距离均增加,治疗组由治疗前288.57±46.10增加至336±40.12,对照组由治疗前的273.94±31.17增加至312±38.69,同组治疗前后对比及治疗后组间对比,差异显著(P<0.05),有统计学意义。说明两组均能明显延长6MWT距离,且治疗组优于对照组。
4.两组治疗后LVDd/cm、LVDs/cm、LVEF及E/A均有所改善。LVEF方而,治疗组由治疗前的45.44±7.19升至56.38±7.07,对照组由治疗前的46.49±7.63升至49.32±6.22：E/A方面,治疗组由治疗前的0.78±0.39升至1.43±0.49,对照组由治疗前的0.79±0.41升至1.08±0.35；LVDd/cm方面,治疗组由治疗前的5.88±1.04下降至5.48±0.86；LVDs/cm方面,治疗组由治疗前的5.86±0.78下降至5.82±0.90。均显示治疗组优于对照组,差异显著,有统计学意义。说明加味参附颗粒有改善慢性心力衰竭患者的收缩及舒张功能,并且有防止心室重构的作用。
5.两组治疗后BNP均有所下降,治疗组由治疗前的754.37±53.10下降至286±52.32；对照组由治疗前的738.64±41.32下降至352±38.6,同组治疗前后比较,差异显著(P<0.05)；组间对比,差异显著(P<0.05)；说明加味参附颗粒有改善患者BNP的作用。
(二)第二部分(动物实验)
1.心率方面：模型组心率高于正常组、曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B(p<0.05)；而加味参附颗粒组A及加味参附颗粒组B改善心率优于曲美他嗪组,组间相比(p<0.05),但加味参附颗粒组A及组B,组间对比差异无统计学意义(P>0.05)
2.心脏重量方面：大鼠造模后心脏重量明显增加,模型组、曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B与正常组对比,差异显著(*P<0.05),有统计学意义；加味参附颗粒组A,即经临床等效量加味参附颗粒干预后,与模型组对比,心脏重量增加有抑制作用,组间对比,差异显著,(P<0.05),有统计学意义；左心室重量指数方面：造模后左心室重量指数升高,与正常组对比,*P<0.05,差异有统计学意义：加味参附颗粒组A、组B、曲美他嗪组与模型组对比,P<0.05,有统计学意义；而加味参附颗粒组A、组B与曲美他嗪组对比,P>0.05,差异无统计学意义；揭示加味参附颗粒有预防心室重构的作用。
3.±dP/dt max方面：曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B±dP/dt max高于模型组(p<0.05)；而加味参附组A及组B更高于曲美他嗪组,但无统计学意义(P>0.05)；
4.血压方面：造模后各组动脉收缩压(SAP)、动脉舒张压(DAP)、左室舒张末压(LVEDP)与正常组对比,差异显著(p<0.01),有统计学意义；与模型组对比,曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B均有明显改善,差异显著(p<0.01),有统计学意义；曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B,组间对比,有差异,但无统计学意义。
5.Na+-K+-ATP酶和Ca2+-ATP酶活性方面：模型组中Na+-K+-ATP酶和Ca2+-ATP酶活性均较低,而曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B较模型组明显升高,与模型组对比,差异显著(P<0.05),有统计学意义；加味参附颗粒组A、组B与曲美他嗪组,组间对比存在差异,但p>0.05,无统计学意义；加味参附颗粒组A、组B,组间对比亦存在差异,同样p>0.05,无统计学意义。
6.心肌超微结构方面：经加味参附颗粒干预后慢性心力衰竭大鼠心肌肌原纤维排列整齐,肌节结构明显,肌丝排列整齐,明暗带清楚,其间可见线粒体及肌浆网,线粒体排列较整齐,结构清楚,嵴结构清晰,未见明显肿胀,线粒体间可见少量脂滴,细胞核核膜较清楚,包膜完整,无结块及边集现象,无空泡形成。
结论
(一)临床研究部分
1.加味参附颗粒可以改善慢性心力衰竭患者的心功能,减轻临床症状,是治疗慢性心力衰竭的有效中成药。
2.加味参附颗粒可以改善慢性心力衰竭患者的中医临床证候。
3.加味参附颗粒可以增加慢性心力衰竭患者的活动耐力。
(二)实验研究部分
1.慢性心力衰竭大鼠造模成功,运用造模方法是腹主动脉缩窄法,操作步骤相对简单,成功率高。
2.加味参附颗粒可以改善慢性心力衰竭模型大鼠的血流动力学,包括心率、血压及±dP/dt max。
3.加味参附颗粒可以改善慢性心力衰竭模型大鼠的心肌超微结构,改善左心室重量指数,有抑制慢性心力衰竭模型大鼠心室重构的作用。
4.加味参附颗粒可以改善慢性心力衰竭模型大鼠Na+-K+-ATP酶和Ca2+-ATP酶活性的抑制作用,进而改善心肌能量代谢。
因此,加味参附颗粒是治疗“心肾阳(气)虚、血瘀水停”证慢性心力衰竭患者的有效中成药,可以改善心脏射血分数、降低BNP,逆转心室重构,提高患者的运动耐量,其可能机制之一为提高心肌能量代谢。
Objective
Modified Shen Fu particles chronic congestive heart failure, exercise tolerance observed in clinical studies; observed in animal experiments on rats with heart failure myocardial ul trastructure and mitochondrial Na+-K+-ATPase enzyme, Ca2+-ATPase activity the impact in terms of energy metabolism, and then explore the possible mechanism of the modified Shen Fu particle treatment of chronic heart failure.
Method
This study consists of two parts, the first part is for the study of patients with chronic heart failure. The second part of the chronie heart failure rat, model for the study.
(A) The first part (clinical research)
In accordance with the principles of randomized controlled study,80patients with chronic heart failure Western diagnostic criteria (NYHA Heart Association functional class Ⅱ, Ⅲ) were divided into treatment group and TCM belong to the "the heart yang (gas) virtual stasis water retention certificate" and the control group, the treatment group selection of flavored Shenfu particles, the control group used the conventional Western medicine treatment. The key observation of patients before and after treatment clinical symptoms, BNP, ef%,E/A,6-minute walk test.
(B) The second part (animal experiments)
Clean SD male rats40, in accordance with the digital tables principles are divided into normal control group, model control group, western medicine group, modified Shen Fu particle group A (clinical equivalent group) and modified Shen Fu particle group B (2times the clinical equivalent amount of group),8rats in each group. In addition to the normal control group, each group first modeling process. After the modeling of each group to the appropriate intervention:control group:to give daily fed with distilled water2ml; model control group:to give daily fed with distilled water2ml; western medicine group:daily gavage5.4mg/kg given qumei He hydrochloride tablets; modified Shen Fu the particle group A:give fed daily6.84g crude drug/kg (equivalent to the clinical effective amount) Modified Shen Fu the particles group B:to give fed daily13.68g of crude drug/kg (equivalent to2times the clinical effective amount) 4weeks. OUTCOME MEASURES:body weight, heart weight, left ventricular mass, heart weight ratio, left ventricular heart than arterial pressure, right ventricular pressure, heart rate, left ventricular pressure maximum rise and fall rate [Max+DP/dt (mmHg/s)], myocardial mi tochondrial structure, mitochondrial Na+-K+-ATP enzyme and Ca2+-ATPase enzyme activity.
Result
(A) The first part (clinical research)
(1)Groups NYHA class compare the efficacy of the treatment group was87.50%, total effective rate was70.00%in the control group, two groups, treatment group, the total effective rate was higher than that in the control group, and the difference was statistically significant (P<0.05).
(2) two sets of Lee's heart failure efficacy of scoring method to compare the treatment group the total effective rate was85.00%, total effective rate was67.50%in the control group, two groups, treatment group, the total effective rate was higher than that in the control group, and the difference was statistically significant (P<0.05).
(3)After treatment6MWT distance increased, the treatment group increased to336by the pre-treatment288.57±46.10±40.12, control group increased to312by the pre-treatment273.94±31.17±38.69, the same group before and after treatment and after treatment groups contrast, the difference was significant (P<0.05) was statistically significant. The two groups could significantly extend the6MWT distance, and the treatment group than the control group.
(4)After treatment LVEF and E/A has been reduced. LVEF, the treatment group before treatment45.44±7.19to56.38±7.07in the control group before treatment46.49±7.63to49.32±6.22; E/A aspects of the treatment group before treatment,0.78±0.39to1.43±0.49, control group before treatment to0.79±0.41increased to1.08±0.35, in terms of both the treatment group than the control group, the difference was significant, statistically significant. Modified Shen Fu particles systolic and diastolic function improved in patients with chronic heart failure.
(5)Treatment after BNP has decreased in the treatment group decreased from754.37±53.10before treatment to286±52.32; control group decreased from738.64±41.32before treatment to352±38.6, compared wi th the group before and after treatment, significant differences (P<0.05); comparison group,the difference was significant (P<0.05); improve patient BNP modified Shen Fu particles
(B) The second part (animal experiments)
(1)Heart rate:the model group heart rate is higher than the normal group, the trimetazidine group of Modified Shen Fu the particle group A modified Shen Fu the particles group B (p<0.05); Modified Shen Fu particle group A and the modified Shen attached particle group B to improve heart rate is better than the trimetazidine group compared between groups (p<0.05), but flavored Shenfu the particle group A and group B, the contrast between the two groups was no significant difference (P>0.05)
(2)Heart weight:Rats in heart weight increased significantly, model group, trimetazidine group, flavored Shenfu particle group A modified Shen Fu the particles group B with the normal group contrast, significant difference (P <0.05), was statistically significant; modified Shen Fu particle group A, which is the the clinical equivalent amount flavored Shenfu particles intervention, with the model group compared the increase in heart weight inhibition, comparison group, the difference was significant (P<0.05), and was statistically significant; left ventricular mass index:modeling elevated left ventricular mass index, compared with the normal group, P<0.05, the difference was statistically significant; Modified Shen Fu the particle group A, group B, Trimetazidine triazine group and model group comparison, P<0.05, statistically significant; modified Shen Fu particle group A, group B with trimetazidine group compared P>0.05, the difference was not statistically significant; reveal Modified Shen Fu particles prevention of ventricular remodeling.
(3)±dP/dt max aspects:trimetazidine group, flavored Shenfu the particle group A and flavored the Shenfu particle group B±dp/dt max higher than model group (p<0.05); Modified Shen Fu group A and group B higher in the trimetazidine group, but not statistically significant (P>0.05);4blood pressure:modeling groups systolic arterial pressure (SAP), diastolic blood pressure (DAP), left ventricular end-diastolic pressure (LVEDP) compared with the normal group, a significant difference (p<0.01) was statistically significant; with the model group compared trimetazidine group, modified Shen Fu the particle group A, Modified Shen Fu the particles group B showed significant improvement, significant difference (p<0.01) was statistically significant;Trimetazidine triazine group, Modified Shen Fu particle group A modified Shen Fu particle group B, group comparison, there are differences, but not statistically significant.
(4)Na+-K-ATP enzyme and Ca2+-ATPase enzyme activity:the model group Na+-K+-ATP enzyme and Ca2+-ATPase enzyme activity were lower, while qumei he triazine group, flavored parameters attached to particles of group A and flavored Shenfu particle group B compared with the model group was significantly increased compared with the model group, the difference was significant (P<0.05), a statistically significant; modified Shen Fu particle group A, group B with trimetazidine group, the contrast between the two groups exist difference, but p>0.05, not statistically significant; modified Shen Fu the particle group A, group B, the contrast between the two groups there are differences between the same p>0.05, not statistically significant. Chronic heart failure after myocardial ultrastructure:flavored Shenfu particles intervention rat cardiac myofibrils arranged in neat rows, the sarcomere structure, neatly myoneme, light and dark with clear, during which the visible mitochondria and sarcoplasmic reticulum, mitochondria arranged in neat, clear structure, the ridge structure is clear, no significant swelling, shows a small amount of lipid droplets in mitochondria,nucleus nuclear membrane more clearly, encapsulated, non-caking and edge set of phenomena, vacuolization.
Conelusion
(A) clinical research component
(1)Modified Shen Fu particles can improve cardiac function in patients with chronic heart failure, reduce symptoms, is an effective medicine treatment of chronic heart failure.
(2)Modified Shen Fu particles can improve clinical medicine chronic heart failure syndromes.
(3)Modified Shen Fu particles can increase endurance activity in patients with chronic heart failure.
(B) Experimental research component
(1) successful model in rats wi th chronic heart fai lure, the use of modeling methods are abdominal aortic coarctation, the steps are relatively simple, high success rate.
(2)Modified Shen Fu particles rats with chronic heart failure can be improved hemodynamics, including heart rate, blood pressure and±dP/dt max.
(3)Modified Shen Fu particles can improve chronic heart failure rat model of myocardial ultrastructure and improve left ventricular mass index, inhibit ventricular remodeling in rats with chronic heart failure role.
(4)Modified Shen Fu particles can improve chronic heart failure rats Na+-K+-ATP enzyme and Ca2+-ATP inhibition of enzyme activity, thereby improving myocardial energy metabolism.
Therefore, the particle is the treatment of Modified Shen Fu "heart yang (gas) deficiency, blood stasis water stop" permit effective medicine in patients with chronic heart failure can improve cardiac ejection fraction, lower BNP, reverse ventricular remodeling, improve patient exercise tolerance, which may be one of the mechanisms to enhance myocardial energy metabolism.
通过临床研究观察加味参附颗粒对慢性心力衰竭患者心功能、运动耐力的影响；并通过动物实验观察其对心衰大鼠心肌超微结构及线粒体Na+-K+-ATP酶、Ca2+-ATP酶活性的影响,进而从能量代谢方面探讨加味参附颗粒治疗慢性心力衰竭的可能机制。
方法
本研究包含两部分内容,第一部分是以慢性心力衰竭患者为研究对象。第二部分是以慢性心力衰竭模型大鼠为研究对象。
(一)第一部分(临床研究)
按照随机对照研究原则,将80例符合慢性心力衰竭西医诊断标准(NYHA心功能分级Ⅱ、Ⅲ)并且中医辨证属于“心肾阳(气)虚、血瘀水停证”患者分为治疗组及对照组,对照组选用常规西医药物治疗,治疗组在对照组的基础上加用加味参附颗粒。观察患者治疗前后临床症状、BNP、EF%、E/A.6分钟步行试验的变化。
(二)第二部分(动物实验)
清洁级SD雄性大鼠40只,按照数字表原则分为正常对照组、模型对照组、西药组、加味参附颗粒组A(临床等效量组)和加味参附颗粒组B(2倍临床等效量组),每组8只大鼠。除正常对照组外各组先进行造模处理。造模成功后,各组予相应的干预：正常对照组：给予每日灌服蒸馏水2ml；模型对照组：给予每日灌服蒸馏水2ml；西药组：给予每日灌服5.4mg/kg曲美他嗪片；加味参附颗粒组A：给予每日灌服6.84g生药/kg(等同于临床效量),加味参附颗粒组B：给予每日灌服13.68g生药/kg(等同于2倍临床效量)
疗程4周。观察指标包括：体重、心脏重量、左室重量、心体重量比、左室全心比、动脉压、右心室内压力、心率、左心室内压最大上升和下降速率[Max±dP/dt (mmHg/s)]、心肌线粒体结构、线粒体Na+-K+-ATP酶和Ca2+-ATP酶活性。
结果
(一)第一部分(临床研究)
1.两组心功能NYHA分级疗效比较,治疗组总有效率87.50%,对照组总有效率为70.00%,两组比较,治疗组总有效率高于对照组,且差异有统计学意义(P<0.05)。
2.两组Lee氏心衰记分法疗效比较,治疗组总有效率85.00%,对照组总有效率为67.50%,两组比较,治疗组总有效率高于对照组,且差异有统计学意义(P<0.05)。
3.两组治疗后6MWT距离均增加,治疗组由治疗前288.57±46.10增加至336±40.12,对照组由治疗前的273.94±31.17增加至312±38.69,同组治疗前后对比及治疗后组间对比,差异显著(P<0.05),有统计学意义。说明两组均能明显延长6MWT距离,且治疗组优于对照组。
4.两组治疗后LVDd/cm、LVDs/cm、LVEF及E/A均有所改善。LVEF方而,治疗组由治疗前的45.44±7.19升至56.38±7.07,对照组由治疗前的46.49±7.63升至49.32±6.22：E/A方面,治疗组由治疗前的0.78±0.39升至1.43±0.49,对照组由治疗前的0.79±0.41升至1.08±0.35；LVDd/cm方面,治疗组由治疗前的5.88±1.04下降至5.48±0.86；LVDs/cm方面,治疗组由治疗前的5.86±0.78下降至5.82±0.90。均显示治疗组优于对照组,差异显著,有统计学意义。说明加味参附颗粒有改善慢性心力衰竭患者的收缩及舒张功能,并且有防止心室重构的作用。
5.两组治疗后BNP均有所下降,治疗组由治疗前的754.37±53.10下降至286±52.32；对照组由治疗前的738.64±41.32下降至352±38.6,同组治疗前后比较,差异显著(P<0.05)；组间对比,差异显著(P<0.05)；说明加味参附颗粒有改善患者BNP的作用。
(二)第二部分(动物实验)
1.心率方面：模型组心率高于正常组、曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B(p<0.05)；而加味参附颗粒组A及加味参附颗粒组B改善心率优于曲美他嗪组,组间相比(p<0.05),但加味参附颗粒组A及组B,组间对比差异无统计学意义(P>0.05)
2.心脏重量方面：大鼠造模后心脏重量明显增加,模型组、曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B与正常组对比,差异显著(*P<0.05),有统计学意义；加味参附颗粒组A,即经临床等效量加味参附颗粒干预后,与模型组对比,心脏重量增加有抑制作用,组间对比,差异显著,(P<0.05),有统计学意义；左心室重量指数方面：造模后左心室重量指数升高,与正常组对比,*P<0.05,差异有统计学意义：加味参附颗粒组A、组B、曲美他嗪组与模型组对比,P<0.05,有统计学意义；而加味参附颗粒组A、组B与曲美他嗪组对比,P>0.05,差异无统计学意义；揭示加味参附颗粒有预防心室重构的作用。
3.±dP/dt max方面：曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B±dP/dt max高于模型组(p<0.05)；而加味参附组A及组B更高于曲美他嗪组,但无统计学意义(P>0.05)；
4.血压方面：造模后各组动脉收缩压(SAP)、动脉舒张压(DAP)、左室舒张末压(LVEDP)与正常组对比,差异显著(p<0.01),有统计学意义；与模型组对比,曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B均有明显改善,差异显著(p<0.01),有统计学意义；曲美他嗪组、加味参附颗粒组A、加味参附颗粒组B,组间对比,有差异,但无统计学意义。
5.Na+-K+-ATP酶和Ca2+-ATP酶活性方面：模型组中Na+-K+-ATP酶和Ca2+-ATP酶活性均较低,而曲美他嗪组、加味参附颗粒组A及加味参附颗粒组B较模型组明显升高,与模型组对比,差异显著(P<0.05),有统计学意义；加味参附颗粒组A、组B与曲美他嗪组,组间对比存在差异,但p>0.05,无统计学意义；加味参附颗粒组A、组B,组间对比亦存在差异,同样p>0.05,无统计学意义。
6.心肌超微结构方面：经加味参附颗粒干预后慢性心力衰竭大鼠心肌肌原纤维排列整齐,肌节结构明显,肌丝排列整齐,明暗带清楚,其间可见线粒体及肌浆网,线粒体排列较整齐,结构清楚,嵴结构清晰,未见明显肿胀,线粒体间可见少量脂滴,细胞核核膜较清楚,包膜完整,无结块及边集现象,无空泡形成。
结论
(一)临床研究部分
1.加味参附颗粒可以改善慢性心力衰竭患者的心功能,减轻临床症状,是治疗慢性心力衰竭的有效中成药。
2.加味参附颗粒可以改善慢性心力衰竭患者的中医临床证候。
3.加味参附颗粒可以增加慢性心力衰竭患者的活动耐力。
(二)实验研究部分
1.慢性心力衰竭大鼠造模成功,运用造模方法是腹主动脉缩窄法,操作步骤相对简单,成功率高。
2.加味参附颗粒可以改善慢性心力衰竭模型大鼠的血流动力学,包括心率、血压及±dP/dt max。
3.加味参附颗粒可以改善慢性心力衰竭模型大鼠的心肌超微结构,改善左心室重量指数,有抑制慢性心力衰竭模型大鼠心室重构的作用。
4.加味参附颗粒可以改善慢性心力衰竭模型大鼠Na+-K+-ATP酶和Ca2+-ATP酶活性的抑制作用,进而改善心肌能量代谢。
因此,加味参附颗粒是治疗“心肾阳(气)虚、血瘀水停”证慢性心力衰竭患者的有效中成药,可以改善心脏射血分数、降低BNP,逆转心室重构,提高患者的运动耐量,其可能机制之一为提高心肌能量代谢。
Objective
Modified Shen Fu particles chronic congestive heart failure, exercise tolerance observed in clinical studies; observed in animal experiments on rats with heart failure myocardial ul trastructure and mitochondrial Na+-K+-ATPase enzyme, Ca2+-ATPase activity the impact in terms of energy metabolism, and then explore the possible mechanism of the modified Shen Fu particle treatment of chronic heart failure.
Method
This study consists of two parts, the first part is for the study of patients with chronic heart failure. The second part of the chronie heart failure rat, model for the study.
(A) The first part (clinical research)
In accordance with the principles of randomized controlled study,80patients with chronic heart failure Western diagnostic criteria (NYHA Heart Association functional class Ⅱ, Ⅲ) were divided into treatment group and TCM belong to the "the heart yang (gas) virtual stasis water retention certificate" and the control group, the treatment group selection of flavored Shenfu particles, the control group used the conventional Western medicine treatment. The key observation of patients before and after treatment clinical symptoms, BNP, ef%,E/A,6-minute walk test.
(B) The second part (animal experiments)
Clean SD male rats40, in accordance with the digital tables principles are divided into normal control group, model control group, western medicine group, modified Shen Fu particle group A (clinical equivalent group) and modified Shen Fu particle group B (2times the clinical equivalent amount of group),8rats in each group. In addition to the normal control group, each group first modeling process. After the modeling of each group to the appropriate intervention:control group:to give daily fed with distilled water2ml; model control group:to give daily fed with distilled water2ml; western medicine group:daily gavage5.4mg/kg given qumei He hydrochloride tablets; modified Shen Fu the particle group A:give fed daily6.84g crude drug/kg (equivalent to the clinical effective amount) Modified Shen Fu the particles group B:to give fed daily13.68g of crude drug/kg (equivalent to2times the clinical effective amount) 4weeks. OUTCOME MEASURES:body weight, heart weight, left ventricular mass, heart weight ratio, left ventricular heart than arterial pressure, right ventricular pressure, heart rate, left ventricular pressure maximum rise and fall rate [Max+DP/dt (mmHg/s)], myocardial mi tochondrial structure, mitochondrial Na+-K+-ATP enzyme and Ca2+-ATPase enzyme activity.
Result
(A) The first part (clinical research)
(1)Groups NYHA class compare the efficacy of the treatment group was87.50%, total effective rate was70.00%in the control group, two groups, treatment group, the total effective rate was higher than that in the control group, and the difference was statistically significant (P<0.05).
(2) two sets of Lee's heart failure efficacy of scoring method to compare the treatment group the total effective rate was85.00%, total effective rate was67.50%in the control group, two groups, treatment group, the total effective rate was higher than that in the control group, and the difference was statistically significant (P<0.05).
(3)After treatment6MWT distance increased, the treatment group increased to336by the pre-treatment288.57±46.10±40.12, control group increased to312by the pre-treatment273.94±31.17±38.69, the same group before and after treatment and after treatment groups contrast, the difference was significant (P<0.05) was statistically significant. The two groups could significantly extend the6MWT distance, and the treatment group than the control group.
(4)After treatment LVEF and E/A has been reduced. LVEF, the treatment group before treatment45.44±7.19to56.38±7.07in the control group before treatment46.49±7.63to49.32±6.22; E/A aspects of the treatment group before treatment,0.78±0.39to1.43±0.49, control group before treatment to0.79±0.41increased to1.08±0.35, in terms of both the treatment group than the control group, the difference was significant, statistically significant. Modified Shen Fu particles systolic and diastolic function improved in patients with chronic heart failure.
(5)Treatment after BNP has decreased in the treatment group decreased from754.37±53.10before treatment to286±52.32; control group decreased from738.64±41.32before treatment to352±38.6, compared wi th the group before and after treatment, significant differences (P<0.05); comparison group,the difference was significant (P<0.05); improve patient BNP modified Shen Fu particles
(B) The second part (animal experiments)
(1)Heart rate:the model group heart rate is higher than the normal group, the trimetazidine group of Modified Shen Fu the particle group A modified Shen Fu the particles group B (p<0.05); Modified Shen Fu particle group A and the modified Shen attached particle group B to improve heart rate is better than the trimetazidine group compared between groups (p<0.05), but flavored Shenfu the particle group A and group B, the contrast between the two groups was no significant difference (P>0.05)
(2)Heart weight:Rats in heart weight increased significantly, model group, trimetazidine group, flavored Shenfu particle group A modified Shen Fu the particles group B with the normal group contrast, significant difference (P <0.05), was statistically significant; modified Shen Fu particle group A, which is the the clinical equivalent amount flavored Shenfu particles intervention, with the model group compared the increase in heart weight inhibition, comparison group, the difference was significant (P<0.05), and was statistically significant; left ventricular mass index:modeling elevated left ventricular mass index, compared with the normal group, P<0.05, the difference was statistically significant; Modified Shen Fu the particle group A, group B, Trimetazidine triazine group and model group comparison, P<0.05, statistically significant; modified Shen Fu particle group A, group B with trimetazidine group compared P>0.05, the difference was not statistically significant; reveal Modified Shen Fu particles prevention of ventricular remodeling.
(3)±dP/dt max aspects:trimetazidine group, flavored Shenfu the particle group A and flavored the Shenfu particle group B±dp/dt max higher than model group (p<0.05); Modified Shen Fu group A and group B higher in the trimetazidine group, but not statistically significant (P>0.05);4blood pressure:modeling groups systolic arterial pressure (SAP), diastolic blood pressure (DAP), left ventricular end-diastolic pressure (LVEDP) compared with the normal group, a significant difference (p<0.01) was statistically significant; with the model group compared trimetazidine group, modified Shen Fu the particle group A, Modified Shen Fu the particles group B showed significant improvement, significant difference (p<0.01) was statistically significant;Trimetazidine triazine group, Modified Shen Fu particle group A modified Shen Fu particle group B, group comparison, there are differences, but not statistically significant.
(4)Na+-K-ATP enzyme and Ca2+-ATPase enzyme activity:the model group Na+-K+-ATP enzyme and Ca2+-ATPase enzyme activity were lower, while qumei he triazine group, flavored parameters attached to particles of group A and flavored Shenfu particle group B compared with the model group was significantly increased compared with the model group, the difference was significant (P<0.05), a statistically significant; modified Shen Fu particle group A, group B with trimetazidine group, the contrast between the two groups exist difference, but p>0.05, not statistically significant; modified Shen Fu the particle group A, group B, the contrast between the two groups there are differences between the same p>0.05, not statistically significant. Chronic heart failure after myocardial ultrastructure:flavored Shenfu particles intervention rat cardiac myofibrils arranged in neat rows, the sarcomere structure, neatly myoneme, light and dark with clear, during which the visible mitochondria and sarcoplasmic reticulum, mitochondria arranged in neat, clear structure, the ridge structure is clear, no significant swelling, shows a small amount of lipid droplets in mitochondria,nucleus nuclear membrane more clearly, encapsulated, non-caking and edge set of phenomena, vacuolization.
Conelusion
(A) clinical research component
(1)Modified Shen Fu particles can improve cardiac function in patients with chronic heart failure, reduce symptoms, is an effective medicine treatment of chronic heart failure.
(2)Modified Shen Fu particles can improve clinical medicine chronic heart failure syndromes.
(3)Modified Shen Fu particles can increase endurance activity in patients with chronic heart failure.
(B) Experimental research component
(1) successful model in rats wi th chronic heart fai lure, the use of modeling methods are abdominal aortic coarctation, the steps are relatively simple, high success rate.
(2)Modified Shen Fu particles rats with chronic heart failure can be improved hemodynamics, including heart rate, blood pressure and±dP/dt max.
(3)Modified Shen Fu particles can improve chronic heart failure rat model of myocardial ultrastructure and improve left ventricular mass index, inhibit ventricular remodeling in rats with chronic heart failure role.
(4)Modified Shen Fu particles can improve chronic heart failure rats Na+-K+-ATP enzyme and Ca2+-ATP inhibition of enzyme activity, thereby improving myocardial energy metabolism.
Therefore, the particle is the treatment of Modified Shen Fu "heart yang (gas) deficiency, blood stasis water stop" permit effective medicine in patients with chronic heart failure can improve cardiac ejection fraction, lower BNP, reverse ventricular remodeling, improve patient exercise tolerance, which may be one of the mechanisms to enhance myocardial energy metabolism.
引文
[1]黄小芳,方永生,袁晓红.充血性心力衰竭患者动态血压昼夜节律、血压变异性特点及临床意义[J].浙江实用医学,2008,13(2)：81-84
[2]王古耀.内科学[M]北京：人民卫生出版社,2005：192
[3]戚文航.心力衰竭的流行病学及治疗进展[J].现代实用医学,2004,16(11)：632-634.
[4]戴闺柱.21世纪慢性心力衰竭指南演变的启示[J].中华心血管病志,2009,37(10)：867-869.
[5]Sakata Y, Yamamoto K, et al.Activation of matrixmetallo ptoteinases precedes left ventricular remodeling in hypertensives heart failure rats:its inhibition as a primary effect of angiotensin-coverting enzyme inhibition[J]. circulation,2004,109(17):2143
[6]Braunwold E, Bivstow MR. congestive heart failure:fifiy years of progress[J]. Circulation,2002,102(20):Ⅳ14-IV23
[7]Bing OHL. Hypothesis:apoptosis may bea mechanism for the transition to heart failure with chronic pressure overload[J]. JMol Cell Cardiol,1994:26:943
[8]Sharov VG, Sabbah HN, Shimoyama H, et al. Evidence of cardiocyte apoptosis in myocardinm of dogs with chronic herat failure[J]. Am J. Pathol,1996:148:141
[9]胡高频,李志梁F.细胞凋亡与充血性心力衰竭[J].心血管病进展,1999：20：282
[10]van deer Meer P, De Boer RA, White HL, et al. The VEGF +405CCpromoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure:a MERITHF substudy[J]. J Cardiac Failure,2005,11 (4):279-284.
[11]吴强,李隆贵D,耿昭华.心肌梗死后心衰大鼠心肌细胞凋亡和凋亡相关基因表达的变化[J].第三军医大学学报,2002,24(4)：434-436
[12]Jackson G, Gibbs C R, Davies M K, et al. ABC of heart failure. Pathophysiology[J]. BMJ,2000,320(7228):167-170.
[13]Millane T, Jackson G, Gibbs C R, et al. ABC of heart failure. Acute and chronic management strategies[J]. BMJ,2000,320(7234):559^562.
[14]董志.药理学[M].北京：人民卫生出版社.第二版.2008,6：155-166.
[15]杨宝峰.药理学[M].第七版. 北京：人民卫生出版社. 第7版.2008,1：251-262.
[16]刘治全.心力衰竭治疗的基石：利尿剂[J].中华心血管病杂志,2002,30(5)：319-320.
[17]戴闺柱.β受体阻滞剂治疗心力衰竭：选择性β1受体阻滞或全受体阻滞[J].中华心血管病杂志,2001,29(11)：696-698.
[18]刘国树.非洋地黄类正性肌力药物的临床应用[J].药物与临床,2002,17(4)：15-18.
[19]刘国树.非洋地黄类正性肌力药物的临床应用现状[J].中华心血管病杂志,2002,30(8)：510-512.
[20]Jackson G, Gibbs C R, Davies M K, et al. ABC of heart failure. Pathophysiology[J]. BMJ,2000,320(7228):167-170.
[21]Millane T, Jackson G, Gibbs C R, et al. ABC of heart failure. Acute and chronic management strategies[J]. BMJ,2000,320(7234):559-562.
[22]Gibbs C R, Jackson G, Lip G Y. ABC of heart failure. Non-drug management [J]. BMJ,2000,320(7231):366-369.
[23]戴闺柱.2005年美国慢性收缩性心力衰竭治疗指南浅析[J].中华心血管病杂志,2005,33(12)：1065、1066.
[24]Poole Wilson PA. ACE inhibitors and ARBs in chronic heart failure:The established,the expected and the pragmatic[J]. Med Clin N Am,2003,87 (4):339.
[25]中华医学会心血管病学会,中华心血管病杂志编辑委员会.慢性收缩性心衰的治疗建议[J].中华心血管病杂志,2002,30(1)：7.
[26]Mitchell GF, Arnold JM, Dunlap ME, et al. Pulsati le hemodynamic effects of candesartan in patients with chronic heart failure:The CHARM Program[J]. Eur J Heart Fai,2006,8 (3):191-197.
[27]Pitt B. A new hope for Aldosterone blockade [J]. Circulation,2004,110(13):1 714-1716.
[28]Pitt B, Zannad F, Remme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med,1999,341(10):709-717.
[29]刘铭,王志禄.肾素—血管紧张素—醛固酮系统及其受体与心血管疾病[J].中华心血管病杂志,2002,30(3)：190-192.
[30]Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after rmyocardial infarction[J]. N Engl J Med,2003,348 (14):1309-1321.
[31]Mcmurray J, Pfeffer M A. New therapeutic options in congestive heart failure:Part Ⅱ[J]. Circulation,2002,105(18):2223-2228.
[32]Mcmurray J, Pfeffer M A. New therapeutic options in congestive heart failure:Part 1[J]. Circulation,2002,105(17):2099-2106.
[33]Cleland JGF.β2blockers for heart failure:Why.which, when and where [J].Med Clin N Am,2003,87(4):329-331.
[34]戴闺柱.心力衰竭生物学治疗的现状和展望[J].中华心血管病杂志,2005,33(10)：873-874.
[35]戴闺柱.心力衰竭生物学治疗的新认识[J].中华心血管病杂志,2000,28(4)：314.
[36]黄峻.心力衰竭治疗的基石：血管紧张素转换酶抑制剂[J].中华心血管病杂志,2002,30(4)：255-257.
[37]张文博.心血管药物应用的新进展[M].北京：人民卫生出版社,2002：137-138.
[38]徐大立,陶以嘉,范永华,等.心力衰竭研究进展[J].心血管病学进展,2004,25(B12)：114-118.
[39]于崇,黄衍寿,吴伟.慢性心力衰竭的非药物治疗进展[J].中西医结合心脑血管病杂志,2005,8(8)：719-722
[40]陈灏珠.实用内科学[M]北京：人民卫生出版社,2001：1245
[41]邵一兵,王正忠,王旭,等.老年心瓣膜病所致顽固性心力衰竭短期血液透析治疗[J].中华医学研究杂志,2003,3(9)：769-771
[42]窦忠东,马锡金,马君秀,等.血液透析治疗顽固性心力衰竭的安全性及疗效观察[J].山东 医药,2004,44(4)：29-30
[43]0'ConnorCM, VelazquezEJ, GardnerLH, etal. Compari son of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy a 25 -year experience from the Duke Cardiovascular Disease Databank. Am JCardi.2002,90(2):101-107
[44]Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator im. plantation trial II[J]. Circulation,2006,113(24):2 810
[45]Mitchell JE, Heilkamp AS, Mark DB, et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial(SCD-HeFT)[J]. Am Heart J,2008。155(3):501
[46]中华医学会心血管病分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12)：1076
[47]Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end. stage heart failure[J]. N Engl Med,2001,345(20):1435
[48]Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1 year results of the REPAIR ·AMI trial[J]. Eur Heart J.2006.27(23):2775
[49]陈少宗4针刺间使穴内关穴对冠心病病人左心功能影响的比较观察[J].针灸临床杂志,1994,10(6)：30
[50]郑关毅,张贵灿.针刺内关穴对冠心病病人左心室功能的影响[J].上海针灸杂志,1997,16(4) ：8
[51]单秋华.电针耳穴心区对心脑血管功能的影响[J].中国针灸,1996,16(6)：9
[52]姜恒源,于纪巧,杨秀梅.穴位埋线治疗冠心病97例[J].上海针灸杂志,1995,14(4)：159
[53]尹克春,吴焕林.邓铁涛治疗心力衰竭经验介绍[J].江苏中医药,2002,23(7)：9—10.
[54]张艳.慢性心衰的中医辨证与分子生物学研究初探[J].中医药学刊,2002,20(4)：477.
[55]宋耀鸿.充血性心力衰竭中医药治法探讨[J].江苏中医药,2003,24(10)：4-5.
[56]薛长玲.董燕平治疗慢性心力衰竭经验[J].中医药学刊,2004,17(4)：2250.
[57]陈洁真,严夏,李俊.严夏用升清降浊法治疗慢性充血性心力衰竭经验[J]. 中医研究,2006,19(1)：60-61.
[58]周仲英.益阴助阳活力血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,1998,12(3)：34.
[59]谭璐芸.郭维琴治疗心力衰竭经验介绍[J].云南中医学院学报,2000,23(2)：43.
[60]朱明军,李彬,王永霞.充血性心力衰竭中医病因病机分析[J].世界中西医结杂,2009,4(1)：11.
[61]朱波.李七一心衰辨治心法[J].江苏中医药,2008,40(12)：18-19.
[62]徐燕,杨爱东,唐靖一,等.严世芸治疗充血性心力衰竭的经验[J]. 上海中医药杂志,2006,40(10)：10-11.
[63]贺泽龙,郭振球.充血性心力衰竭中医证候的临床回顾性调查研究[J].湖南中医学院学 报,2003,23(5)：33、36.
[64]张瑞华,焦增绵,马丽红.慢性充血性心力衰竭的中医辨证论治[J].中国医药学报,2002,17(7)：440-441.
[65]周文斌,王继娟,陈力,等.黄春林教授经验方治疗慢性心力衰竭150例临床观察[J].新中医,2009,41(7)：39-41.
[66]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J]. 中华实用中西医杂志,2005,18(23)：1780-1781.
[67]王振涛,韩丽华,朱明军,等.孙建芝教授辨治慢性充血.性心力衰竭经验[J].四川中医,2008,26(5)：2-3.
[68]连林芳.辨证分型治疗充血性心力衰竭例析[J].实用中医内科杂志,2004,8(4)：301302.
[69]李慧.慢性充血性心力衰竭辨治探讨[J].山西中医,2009,25(2)：1-3.
[70]李高兴,指导：李南夷.益气温阳活血利水治疗充血性心力衰竭略述[J].中医药学刊,2006,24(9)：1698-1700
[71]中华医学会心血管病学分会.慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1)：7
[72]安海英,黄丽娟,金敬善,等.益气温阳和活血利水法对充血性心力衰竭患者神经内分泌系统的影响[J].中国中西医杂志,2003,36(5)：349-351
[73]红永敦,冼绍祥,陈宇朋,等.益气温阳活血利水中药对充血性心力衰竭患者内皮素及一氧化氮的影响[J].中药新药与临床药理,2000,11(3)：71
[74]李文杰.强心宁对CHF大鼠心功能及超微结构影响的实验研究[J].中医药学刊,2003,21(3)：368-369
[75]杨丁友,徐浩,段学忠.慢衰灵口服液对心肾阳虚型充血性心力衰竭j患者细胞因子的干预作用[J].中国中西医结合杂志,2002,22(12)：899-901
[76]张腾,曹洪欣,盛小禹,等.温心胶囊对大鼠实验性缺血心肌细胞调亡及Bcl-2、Fas蛋白的表达的影响[J].中国中西医结合杂志,2003,23(10)：769-771
[77]徐丽.中医药治疗充血性心力衰竭的作用机理研究[J].长春中医学院学报,2002,18(1)49-50
[78]白民刚,刘玉华,谷刚,等.康心力胶囊治疗充血性心力衰竭临床与实验研究[J].中医杂志,2001,42(3)：156-158
[79]龙新生,熊曼琪,朱章志,等.加味真武汤对CHF少阴病阳虚水停证兔自由基三项的影响[J].实用中西医结合杂志,1998,26(6)：431-435
[80]杨道文,孙建芝.心衰康对实验性心力衰竭心肌线粒体的影响的电镜研究[J].北京中医药大学学报,1996,19(5)：64-68
[81]胡元会,车维新,曹雪滨,等.心复康口服液对大鼠实验心衰模型心肌细胞Ca2+-ATPase及琥珀酸脱氧酶活性的影响[J].中国医药学报,2000,15(2)：31-33
[82]阎亚非,吴时达,吴桐.温阳健心灵对充血性力衰竭患者血流动力学的影响[J].中国中西医结合杂志,2001,21(6)：447
[83]李帆.温阳利水、益气活血法治疗慢性充血性心力衰竭临床观察[J].中国中医急症,2006,15(11)：1212-1213
[84]张忠,钟晓玲,罗陆一,等.益气温阳、活血利水法对充血性心力衰竭的辅助治疗作用[J].广州中医药大学学报,2007,24(3)：201-203
[85]杜玉竹.益气活血温阳利水治疗慢性心功能不全32例[J].实用中医内科杂志,2003,17(3)：203
[86]安海英,黄丽娟,金敬善,等.益气温阳和活血利水法对充血性心力衰竭患者神经内分泌系统的影响[J].中国中西医结合杂志,2002,22(5)：349-352
[87]田俊,冯继伟,张建峰,等.中西医结合治疗慢性充血性心力衰竭临床观察[J].上海中医药杂志,2004,38(4)：10-11
[88]宋庆桥,高改地,付亚龙.心衰颗粒对慢性充血性心力衰竭患者血管紧张素Ⅱ、醛固酮的影响[J].北京中医杂志,2002,21(3)：134-135
[89]冼绍祥,黄平东,黄衍寿,等.益气、温阳、活血、利水药物不同配伍对离体豚鼠乳头肌的作用[J].湖南中医学院学报,2005,25(4)：17-19
[90]刘革命,郭新侠,谢艳玲,等.温阳益气活血利水中药对慢性心力衰竭患者左室舒张功能的影响[J].中国中医急症,2005,14(8)：711-741
[91]李金祥,方居正.温阳益气活血利水法对慢性心衰患者血浆肾素系统的影响[J].中国中医急症,2006,15(5)：451,468
[92]张忠,钟晓玲,罗陆一,等.益气温阳、活血利水法对充血性心力衰竭患者神经内分泌因子的影响[J].江西中医药,2006,37(8)：15-16
[93]洪永敦,冼绍祥,陈宇鹏,等.益气温阳活血利水中药对充血性心力衰竭患者内皮素及一氧化氮的影响[J].中药新药与临床药理,2000,11(2)：71-73
[94]沈淑静,黄平东,黄衍寿,等.益气温阳活血利水法对心力衰竭兔模型神经内分泌的影响[J].中医研究,2006,19(12)：19-21
[95]Cooper KH. A mean of assessing maximal oxygen in2take[J]. JAMA,1968,203:135-138.
[96]McGavin C R, Gupta S P, McHardy G J R. Twelve-minute walking test for assessing disability in chronic bronchitis [J]. Br Med J,1976,1 (6013):822-823.
[97]Butland RJA, Pang J, Gross E R, etal. Two2, Six2, and 122 minute walking tests in respiratory disease [J].Br Med J,1982,284 (6329):1607-1608.
[98]Guyatt G H, Sullivan MJ, Thompson P J, et al. The 6-minutewalk:a new measure of exercise capacity in patients with chronic heart failure[J]. Can Med Assoc J,1985, 132 (8):919-923.
[99]Knox A J, Morrison JFJ, Muers M F. Reproducibility of walking test results in chronic obstructive airways disease [J].Thorax,1988,43(5):388-392.
[100]中华心血管病杂志编委会心血管药物对策专题组.心血管药物临床试验评价方法建议V.抗心力衰竭药[J].中华心血管病杂志,1998,26：405-413.
[101]Q uit tanM, W iesinger GF, Crevenna R, et al. Crosscultural adap tat ion of the Minneso ta Living w ith Heart Failure Q uest ionnaire fo r German2speak ing patients[J]. J RehabilM ed,2001,33:182-186.
[102]Cahalin L P, M ather MA, Sem igran MJ, et al. The six minute w alk test p redicts peak oxygen up take and survival in pat ients w ith advanced heart failure [J]. Chest, 1996,110:3252331.
[103]惠海鹏,许顶立,刘煜,等.6分钟步行实验在充血性心力衰竭患者中的应用价值[J].现代康复,2001,5：36-37.
[104]Bitter V, Weiner D H, Yusuf S, et al. Prediction of mortality and morbidity with a 62minute walk test in patients with left ventricular dysfunction [J]. JAMA,1993, 270 (14):1702-1707.
[105]Zugck C, Kruger C, Durr S, et al.Is the 62minute walk test are liable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? [J]. Eur Heart J 2000,21(7):540-549.
[106]Opasich C, Pinna G D, Mazzaa A, et al. Reproducibility of the six minute walking test in chronic congestive heart failure patients:pracitical implications [J]. Am J Cardiol,1998,81(12):1497-1500.
[107]Lipkin D P. The role of exercise testing in chronic heart failure[J]. Br Heart J, 1987,58(6):559-566.
[108]Myers J, Walsh D, Buchanan N, et al. Can maximal cardiopulmonary capacity be recognized by plateau in oxygen up take? [J].Chest,1989,96(6):1312-1316.
[109]Riley M, McParland J, Stanford C F, et al. Oxygen consumption during corridor walk testing in chronic cardiac failure[J]. Eur Heart J,1992,13 (6):789-793.
[110]Canal in L P, Michaier M A, Semigran M J, et al. The six2 minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure [J]. Chest 1996,110(2):325-332.
[111]Morales F J, Martinez A, Mendez M, et al. A shuttle walk test for assessment of functional capacity in chronic heart failure [J].Am Heart J,1999,138 (2 Pt 1) 291-298.
[112]Bitter V. Determining prognosis in congestive heart failure:Role of the 62minute walk test [J]. Am Heart J,1999,138 (4 Pt 1):593-596.
[113]Lucas C, Stevenson L W, Johnson W, et al. The 62minute walk and peak oxygen consumption in advanced heart failure:aerobic capacity and survival [J]. Am Heart J,1999,138 (4 Pt 1):618-624.
[114]Zugck C, Kruger C, Durr S, et al. Is the 6-minute walk test are liable substitute for peak oxygen uptake in patients wi th dilated cardiomyopathy? [J].Eur Heart J,2000, 21(7):540-549.
[115]Shah M R,Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six2minute walk in patients with advanced chronic heart failure secondary to ischemic or nonischemic cardiomyopathy [J].Am J Cardiol,2001,88 (9):987-993.
[116]Roul G, Germain P, Bareiss P, et al. Does the 62minute walk test predict the prognosis in patients with NYI1A class Ⅱ or Ⅲchronic heart failure [J]?Am Heart J 1998,136(3):449-457.
[117]Mungall 1 P F,Hainsworth R. Assessment of respiratory function in patients with chronic obstructive airways disease [J]. Thorax,1979,34(2):254-258.
[118]Demers C, McKelvie R S, Negassa A, et al. Reliability,validity, and responsiveness of the six2minute walk test in patients with heart failure[J]. Am Heart J,2001,142 (4):6982703.
[119]Lipkin D P, Scriven A J, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure [J].BrMed J,1986,292(6521):653-655.
[120]Cahalin L P, Pappagianopoulos P, Prevost S, et al.The relationship of the 62min walk test to maximal oxygen consumption in transplant candidates with end2stage lung disease[J]. Chest,1995,108(2):452-459.
[121]王大英,范维琥.6分钟步行试验在慢性充血性心力衰竭中的应用[J].临床荟萃,2003,18(7)：412-413
[122]Conley K E, Esselman P C, Jubrias S A, et al. Aging, muscle properties and maximal 02 uptake rate in humans. J Physiol,2000,526:211-217.
[123]Forissier J F, Vernochet P, Bertrand P, et al. Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. Eur J Heart Fail,2001,3:335-342.
[124]Butland R J A, Pang J, Gross E R, et al. Two2, six2 and 122 minute walking test in respiratory disease. Br Med J,1982,284:1607-1608.
[125]Cahalin L P, Mathier M A, Semigran M J, et al. The six minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest,1996, 110:325-332.
[126]Faggiano P, D'Aloia A, Gualeni A, et al. Assessment of oxygen uptake during the six minute walk test in patients with heart failure. Preliminary experience using a portable device. Am Heart J,1997,134:203-206.
[127]姜虹,戴闺柱.心力衰竭患者心功能的评定—6分钟步行试验与运动峰耗氧量对比研究.临床心血管病杂志,1995,11(5)：270-272.
[128]唐艳芬,高想,蒋凤荣,等.利心冲剂对阿霉素所致慢性心力衰竭大鼠T I M P 21、T G F 2β的影响[J].上海中医药杂志,2009,43(10)：62-64
[129]李玉玲,杨建业,唐俊明,等.阿霉素诱导大鼠心衰模型不同方案的比较[J].中国比较医学杂志,2006,16(2)：93-96.
[130]芦玲巧,曾翔俊,郝刚.大鼠心力衰竭模型的构建与鉴定[J].中国比较医学杂志,2012,22(8)：22、25.
[131]褚春,杨军,谭芳,等.腹主动脉缩窄大鼠心力衰竭时心室肌细胞电生理失稳态及Ito的变化[J].医学信息：上旬刊,2010,23(17)：3107-3108.
[132]褚春,杨军,王苏燕,等.厄贝沙坦对心力衰竭大鼠心肌电生理失稳态和心室肌细胞I_(Ca-L)电流的影响[J].中南医学科学杂志,2012,40(1)：42-46.
[133]Heinke M Y, Wheeler C H, Yan J X, et al. Changes in myocardial protein expression in pacing-induced canine heart failure[J]. Electrophoresis,1999,20(10):2086-2093.
[134]Montgomery C, Hamilton N, Ianuzzo C D. Energy status of the rapidly paced canine myocardium in congestive heart failure[J]. J Appl Physiol,1992,73(6):2363-2367.
[135]Heinke M Y, Wheeler C H, Yan J X, et al. Changes in myocardial protein expression in pacing-induced canine heart failure[J]. Electrophoresis,1999,20(10):2086-2093.
[136]Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy[J]. Circulation,1995,92(8):2306-2317.
[137]邓青秀,彭成.中医药心力衰竭动物模型的研究现状[J].四川动物,2011,30(2)：296-300.
[138]周文武,林玲,陈军,等冠脉结扎法制做大鼠心肌缺血模型[J].中国实验动物学报,2004,12(4)：226—231
[139]朱文晖,张晓红,肖渊茗.超声心动图评价心力衰竭大鼠模型心功能改变[J].中南大学学报：医学版,2009,34(5)：453-456.
[142]Xie ZJ, Cail T. Na+ -K+ -ATPase-Mediated Signal Transduction:from protein interaction to cellular function [J]. Mol Interv,2003,3(3):157-168.
[143]Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure [J]. Circulation, 2006,114(20):2130-2137.
[144]Halbirk M, Norrelund H, Moller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function [J]. Am J Physiol Heart Circ Physiol,2010,299 (4):H1220-1225.
[145]Abozguia K, Elliott P, McKenna W, et al.Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy [J]. Circulation,2010,122 (16):1562-1569.
[146]Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure [J].Herz,2002,27 (7):621-636.
[147]Bristow M. Etomoxir:a new approach to treatment of chronic heart failure [J]. Lancet, 2000,356 (9242):1621-1622.
[148]Holubarsch CJ, Rohrbach M, Karrasch M, et al. A doubleblind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure:the ERGO (etomoxir for the recovery of glucose oxidation) study [J]. Clin Sci (Lond),2007,113 (4):205-212.
[149]KANTOR P F, LUCIEN A, KOZAK R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid to glucose by inhibiting mitochondrial long-chain 3 ketoacyl conzyme A thiolase[J]. Circ Res,2000,86:580-586.
[150]Fragasso G, Palloshi A, Puccetti P, et al.A randomized clinical trial of trimetazidine, apartial free fatty acid oxidation inhibitor, in patients with heart failure [J].J Am Coll Cardiol,2006,48 (5):992-998.
[151]Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy [J].Circulation, 2008,118(12):1250-1258.
[152]El-Kady T, El-Sabban K, Gabaly M, et al.Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy:a24-month study [J]. Am J Cardiovasc Drugs,2005,5 (4):271-278.
[153]Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure [J].Circ Res,2002,91 (4):278-280.
[154]Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure [J].Am J Physiol Heart Circ Physiol,2008,295 (5):H2149-2155.
[155]Ferrari R, Merli E, Cicchitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases:a review [J].Ann N Y Acad Sci,2004,1033:79-91.
[156]Mingorance C, Rodriguez-Rodriguez R, Justo ML, et al. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders [J].Vasc Health Risk Manag,2011,7:169-176.
[157]Serati AR, Motamedi MR, Emami S, et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms [J]. Cardiology,2010,116(3):178-182.
[158]徐希奇,荆志成,蒋鑫,等.静脉注射左卡尼汀治疗肺动脉高压并右心功能障碍疗效观察[J].中华心血管病杂志,2010,38(2)：152-155
[159]黄俊.慢性心力衰竭诊断和治疗2012：现状和进步[J].心血管病学进展,2012,33(1)：1-5
[160]黄培红,靳利利,李典鸿,等.加味参附颗粒配合心脏康复疗法治疗慢性心衰临床观察[J].按摩与康复医学,2011,2(16)：19-20.
[161]苏慧,靳利利,李典鸿,等.加味参附颗粒改善慢性心力衰竭患者生存质量的临床研究[J].福建中医药,2011,42(5)：27-29.
[162]黄培红,靳利利,刘秋江,等.加味参附颗粒对慢性心力衰竭患者预后的影响[J].福建中医药,2011,42(5)：19-20.
[163]靳利利,刘秋江,李典鸿,等.加味参附颗粒对慢性心功能不全患者心功能及血浆脑钠肽的影响[J].广州中医药大学学报,2011,28(5)：468-470.
[164]卞继芳,丁达,吕娜,等.加味参附颗粒治疗缓慢性心律失常30例临床研究[J].国医论坛,2009,24(2)：21、22.
[165]卞继芳,丁达,王清海,等.加味参附颗粒治疗缓慢性心律失常的食道电生理研究[J].河南中医学院学报,2009,24(2)：34-35.
[166]袁丁,靳利利,李典鸿,等.加味参附颗粒治疗慢性心力衰竭疗效分析[J].吉林中医药,2011,31(7)：633-634.
[167]李典鸿,王清海,靳利利,等.加味参附颗粒治疗冠心病合并心功能不全疗效观察[J].实用中医内科杂志,2009(11).
[168]杨思华,王清海,李爱华,等.加味参附颗粒治疗顽固性心力衰竭的超声临床疗效评价[J].新中医,2004,36(5)：33-34.
[169]黄琳,王清海,李典鸿,等.加味参附颗粒治疗慢性肺心病心力衰竭46例临床观察[J].中国中医急症,2003,12(6)：507-508.
[170]李慧,李爱华,刘乡,等.加味参附颗粒治疗充血性心力衰竭及对甲状腺激素的影响[J].中国中医药信息杂志,2005,12(2)：14-15.
[171]江儒文,王清海.加味参附颗粒治疗充血性心力衰竭的研究进展[J].中华中医药学刊,2008,26(11)：2371-2372.
[172]黄琳,于清海,李典鸿,等.加味参附颗粒对慢性心力衰竭患者神经内分泌的影响[J].中华中医药学刊,2008,26(4)：791-792.
[173]李慧,王清海,李爱华,等.加味参附颗粒对充血性心力衰竭病人血流动力学的影响[J].中西医结合心脑血管病杂志,2005,3(2)：100-101.
[174]杨思华,王清海,陈宁,等.加味参附颗粒对顽固性心力衰竭病人心功能的影响[J].中西医结合心脑血管病杂志,2004,2(7)：383-384.
[175]祝世讷.阴阳的本质究竟是什么.山东中医学院学报,1996,(1)：2-6.
[176]杨武功,杨滨.中医阴阳的物理本质.中国中医基础医学杂志,1995,(3)：53-54.
[177]张永忠.论人的阴阳与代谢的关系.中国中医基础医学杂志,1999,5(11)：57-60
[178]Conley K E, Esselman P C, Jubrias S A, et al. Aging, muscle properties and maximal 02 uptake rate in humans. J Physiol,2000,526:211-217.
[179]褚春,杨军,谭芳,等.腹主动脉缩窄大鼠心力衰竭时心室肌细胞电生理失稳态及Ito的变化[J].医学信息：上旬刊,2010,23(17)：3107-3108.
[180]褚春,杨军,王苏燕,等.厄贝沙坦对心力衰竭大鼠心肌电生理火稳态和心室肌细胞I_(Ca-L)电流的影响[J].中南医学科学杂志,2012,40(1)：42-46.
[181]Fischer M, Baessler A, Hense H W, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample[J]. Eur Heart J,2003,24(4):320-328.
[182]Fragasso G, Palloshi A, Puccetti P, et al. A randomized cl inical trim of trimetazidine, a partial free fatty acids oxidation inhibitor。in patients wi th heart failure. J Am Coil Cardiol。2006,48:992-998.
[2]王古耀.内科学[M]北京：人民卫生出版社,2005：192
[3]戚文航.心力衰竭的流行病学及治疗进展[J].现代实用医学,2004,16(11)：632-634.
[4]戴闺柱.21世纪慢性心力衰竭指南演变的启示[J].中华心血管病志,2009,37(10)：867-869.
[5]Sakata Y, Yamamoto K, et al.Activation of matrixmetallo ptoteinases precedes left ventricular remodeling in hypertensives heart failure rats:its inhibition as a primary effect of angiotensin-coverting enzyme inhibition[J]. circulation,2004,109(17):2143
[6]Braunwold E, Bivstow MR. congestive heart failure:fifiy years of progress[J]. Circulation,2002,102(20):Ⅳ14-IV23
[7]Bing OHL. Hypothesis:apoptosis may bea mechanism for the transition to heart failure with chronic pressure overload[J]. JMol Cell Cardiol,1994:26:943
[8]Sharov VG, Sabbah HN, Shimoyama H, et al. Evidence of cardiocyte apoptosis in myocardinm of dogs with chronic herat failure[J]. Am J. Pathol,1996:148:141
[9]胡高频,李志梁F.细胞凋亡与充血性心力衰竭[J].心血管病进展,1999：20：282
[10]van deer Meer P, De Boer RA, White HL, et al. The VEGF +405CCpromoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure:a MERITHF substudy[J]. J Cardiac Failure,2005,11 (4):279-284.
[11]吴强,李隆贵D,耿昭华.心肌梗死后心衰大鼠心肌细胞凋亡和凋亡相关基因表达的变化[J].第三军医大学学报,2002,24(4)：434-436
[12]Jackson G, Gibbs C R, Davies M K, et al. ABC of heart failure. Pathophysiology[J]. BMJ,2000,320(7228):167-170.
[13]Millane T, Jackson G, Gibbs C R, et al. ABC of heart failure. Acute and chronic management strategies[J]. BMJ,2000,320(7234):559^562.
[14]董志.药理学[M].北京：人民卫生出版社.第二版.2008,6：155-166.
[15]杨宝峰.药理学[M].第七版. 北京：人民卫生出版社. 第7版.2008,1：251-262.
[16]刘治全.心力衰竭治疗的基石：利尿剂[J].中华心血管病杂志,2002,30(5)：319-320.
[17]戴闺柱.β受体阻滞剂治疗心力衰竭：选择性β1受体阻滞或全受体阻滞[J].中华心血管病杂志,2001,29(11)：696-698.
[18]刘国树.非洋地黄类正性肌力药物的临床应用[J].药物与临床,2002,17(4)：15-18.
[19]刘国树.非洋地黄类正性肌力药物的临床应用现状[J].中华心血管病杂志,2002,30(8)：510-512.
[20]Jackson G, Gibbs C R, Davies M K, et al. ABC of heart failure. Pathophysiology[J]. BMJ,2000,320(7228):167-170.
[21]Millane T, Jackson G, Gibbs C R, et al. ABC of heart failure. Acute and chronic management strategies[J]. BMJ,2000,320(7234):559-562.
[22]Gibbs C R, Jackson G, Lip G Y. ABC of heart failure. Non-drug management [J]. BMJ,2000,320(7231):366-369.
[23]戴闺柱.2005年美国慢性收缩性心力衰竭治疗指南浅析[J].中华心血管病杂志,2005,33(12)：1065、1066.
[24]Poole Wilson PA. ACE inhibitors and ARBs in chronic heart failure:The established,the expected and the pragmatic[J]. Med Clin N Am,2003,87 (4):339.
[25]中华医学会心血管病学会,中华心血管病杂志编辑委员会.慢性收缩性心衰的治疗建议[J].中华心血管病杂志,2002,30(1)：7.
[26]Mitchell GF, Arnold JM, Dunlap ME, et al. Pulsati le hemodynamic effects of candesartan in patients with chronic heart failure:The CHARM Program[J]. Eur J Heart Fai,2006,8 (3):191-197.
[27]Pitt B. A new hope for Aldosterone blockade [J]. Circulation,2004,110(13):1 714-1716.
[28]Pitt B, Zannad F, Remme W J, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med,1999,341(10):709-717.
[29]刘铭,王志禄.肾素—血管紧张素—醛固酮系统及其受体与心血管疾病[J].中华心血管病杂志,2002,30(3)：190-192.
[30]Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after rmyocardial infarction[J]. N Engl J Med,2003,348 (14):1309-1321.
[31]Mcmurray J, Pfeffer M A. New therapeutic options in congestive heart failure:Part Ⅱ[J]. Circulation,2002,105(18):2223-2228.
[32]Mcmurray J, Pfeffer M A. New therapeutic options in congestive heart failure:Part 1[J]. Circulation,2002,105(17):2099-2106.
[33]Cleland JGF.β2blockers for heart failure:Why.which, when and where [J].Med Clin N Am,2003,87(4):329-331.
[34]戴闺柱.心力衰竭生物学治疗的现状和展望[J].中华心血管病杂志,2005,33(10)：873-874.
[35]戴闺柱.心力衰竭生物学治疗的新认识[J].中华心血管病杂志,2000,28(4)：314.
[36]黄峻.心力衰竭治疗的基石：血管紧张素转换酶抑制剂[J].中华心血管病杂志,2002,30(4)：255-257.
[37]张文博.心血管药物应用的新进展[M].北京：人民卫生出版社,2002：137-138.
[38]徐大立,陶以嘉,范永华,等.心力衰竭研究进展[J].心血管病学进展,2004,25(B12)：114-118.
[39]于崇,黄衍寿,吴伟.慢性心力衰竭的非药物治疗进展[J].中西医结合心脑血管病杂志,2005,8(8)：719-722
[40]陈灏珠.实用内科学[M]北京：人民卫生出版社,2001：1245
[41]邵一兵,王正忠,王旭,等.老年心瓣膜病所致顽固性心力衰竭短期血液透析治疗[J].中华医学研究杂志,2003,3(9)：769-771
[42]窦忠东,马锡金,马君秀,等.血液透析治疗顽固性心力衰竭的安全性及疗效观察[J].山东 医药,2004,44(4)：29-30
[43]0'ConnorCM, VelazquezEJ, GardnerLH, etal. Compari son of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy a 25 -year experience from the Duke Cardiovascular Disease Databank. Am JCardi.2002,90(2):101-107
[44]Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator im. plantation trial II[J]. Circulation,2006,113(24):2 810
[45]Mitchell JE, Heilkamp AS, Mark DB, et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial(SCD-HeFT)[J]. Am Heart J,2008。155(3):501
[46]中华医学会心血管病分会,中华心血管病杂志编辑委员会.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12)：1076
[47]Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end. stage heart failure[J]. N Engl Med,2001,345(20):1435
[48]Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1 year results of the REPAIR ·AMI trial[J]. Eur Heart J.2006.27(23):2775
[49]陈少宗4针刺间使穴内关穴对冠心病病人左心功能影响的比较观察[J].针灸临床杂志,1994,10(6)：30
[50]郑关毅,张贵灿.针刺内关穴对冠心病病人左心室功能的影响[J].上海针灸杂志,1997,16(4) ：8
[51]单秋华.电针耳穴心区对心脑血管功能的影响[J].中国针灸,1996,16(6)：9
[52]姜恒源,于纪巧,杨秀梅.穴位埋线治疗冠心病97例[J].上海针灸杂志,1995,14(4)：159
[53]尹克春,吴焕林.邓铁涛治疗心力衰竭经验介绍[J].江苏中医药,2002,23(7)：9—10.
[54]张艳.慢性心衰的中医辨证与分子生物学研究初探[J].中医药学刊,2002,20(4)：477.
[55]宋耀鸿.充血性心力衰竭中医药治法探讨[J].江苏中医药,2003,24(10)：4-5.
[56]薛长玲.董燕平治疗慢性心力衰竭经验[J].中医药学刊,2004,17(4)：2250.
[57]陈洁真,严夏,李俊.严夏用升清降浊法治疗慢性充血性心力衰竭经验[J]. 中医研究,2006,19(1)：60-61.
[58]周仲英.益阴助阳活力血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,1998,12(3)：34.
[59]谭璐芸.郭维琴治疗心力衰竭经验介绍[J].云南中医学院学报,2000,23(2)：43.
[60]朱明军,李彬,王永霞.充血性心力衰竭中医病因病机分析[J].世界中西医结杂,2009,4(1)：11.
[61]朱波.李七一心衰辨治心法[J].江苏中医药,2008,40(12)：18-19.
[62]徐燕,杨爱东,唐靖一,等.严世芸治疗充血性心力衰竭的经验[J]. 上海中医药杂志,2006,40(10)：10-11.
[63]贺泽龙,郭振球.充血性心力衰竭中医证候的临床回顾性调查研究[J].湖南中医学院学 报,2003,23(5)：33、36.
[64]张瑞华,焦增绵,马丽红.慢性充血性心力衰竭的中医辨证论治[J].中国医药学报,2002,17(7)：440-441.
[65]周文斌,王继娟,陈力,等.黄春林教授经验方治疗慢性心力衰竭150例临床观察[J].新中医,2009,41(7)：39-41.
[66]武蕾,何红涛.汪慰寒教授中医药治疗慢性心衰经验[J]. 中华实用中西医杂志,2005,18(23)：1780-1781.
[67]王振涛,韩丽华,朱明军,等.孙建芝教授辨治慢性充血.性心力衰竭经验[J].四川中医,2008,26(5)：2-3.
[68]连林芳.辨证分型治疗充血性心力衰竭例析[J].实用中医内科杂志,2004,8(4)：301302.
[69]李慧.慢性充血性心力衰竭辨治探讨[J].山西中医,2009,25(2)：1-3.
[70]李高兴,指导：李南夷.益气温阳活血利水治疗充血性心力衰竭略述[J].中医药学刊,2006,24(9)：1698-1700
[71]中华医学会心血管病学分会.慢性收缩性心力衰竭治疗建议[J].中华心血管病杂志,2002,30(1)：7
[72]安海英,黄丽娟,金敬善,等.益气温阳和活血利水法对充血性心力衰竭患者神经内分泌系统的影响[J].中国中西医杂志,2003,36(5)：349-351
[73]红永敦,冼绍祥,陈宇朋,等.益气温阳活血利水中药对充血性心力衰竭患者内皮素及一氧化氮的影响[J].中药新药与临床药理,2000,11(3)：71
[74]李文杰.强心宁对CHF大鼠心功能及超微结构影响的实验研究[J].中医药学刊,2003,21(3)：368-369
[75]杨丁友,徐浩,段学忠.慢衰灵口服液对心肾阳虚型充血性心力衰竭j患者细胞因子的干预作用[J].中国中西医结合杂志,2002,22(12)：899-901
[76]张腾,曹洪欣,盛小禹,等.温心胶囊对大鼠实验性缺血心肌细胞调亡及Bcl-2、Fas蛋白的表达的影响[J].中国中西医结合杂志,2003,23(10)：769-771
[77]徐丽.中医药治疗充血性心力衰竭的作用机理研究[J].长春中医学院学报,2002,18(1)49-50
[78]白民刚,刘玉华,谷刚,等.康心力胶囊治疗充血性心力衰竭临床与实验研究[J].中医杂志,2001,42(3)：156-158
[79]龙新生,熊曼琪,朱章志,等.加味真武汤对CHF少阴病阳虚水停证兔自由基三项的影响[J].实用中西医结合杂志,1998,26(6)：431-435
[80]杨道文,孙建芝.心衰康对实验性心力衰竭心肌线粒体的影响的电镜研究[J].北京中医药大学学报,1996,19(5)：64-68
[81]胡元会,车维新,曹雪滨,等.心复康口服液对大鼠实验心衰模型心肌细胞Ca2+-ATPase及琥珀酸脱氧酶活性的影响[J].中国医药学报,2000,15(2)：31-33
[82]阎亚非,吴时达,吴桐.温阳健心灵对充血性力衰竭患者血流动力学的影响[J].中国中西医结合杂志,2001,21(6)：447
[83]李帆.温阳利水、益气活血法治疗慢性充血性心力衰竭临床观察[J].中国中医急症,2006,15(11)：1212-1213
[84]张忠,钟晓玲,罗陆一,等.益气温阳、活血利水法对充血性心力衰竭的辅助治疗作用[J].广州中医药大学学报,2007,24(3)：201-203
[85]杜玉竹.益气活血温阳利水治疗慢性心功能不全32例[J].实用中医内科杂志,2003,17(3)：203
[86]安海英,黄丽娟,金敬善,等.益气温阳和活血利水法对充血性心力衰竭患者神经内分泌系统的影响[J].中国中西医结合杂志,2002,22(5)：349-352
[87]田俊,冯继伟,张建峰,等.中西医结合治疗慢性充血性心力衰竭临床观察[J].上海中医药杂志,2004,38(4)：10-11
[88]宋庆桥,高改地,付亚龙.心衰颗粒对慢性充血性心力衰竭患者血管紧张素Ⅱ、醛固酮的影响[J].北京中医杂志,2002,21(3)：134-135
[89]冼绍祥,黄平东,黄衍寿,等.益气、温阳、活血、利水药物不同配伍对离体豚鼠乳头肌的作用[J].湖南中医学院学报,2005,25(4)：17-19
[90]刘革命,郭新侠,谢艳玲,等.温阳益气活血利水中药对慢性心力衰竭患者左室舒张功能的影响[J].中国中医急症,2005,14(8)：711-741
[91]李金祥,方居正.温阳益气活血利水法对慢性心衰患者血浆肾素系统的影响[J].中国中医急症,2006,15(5)：451,468
[92]张忠,钟晓玲,罗陆一,等.益气温阳、活血利水法对充血性心力衰竭患者神经内分泌因子的影响[J].江西中医药,2006,37(8)：15-16
[93]洪永敦,冼绍祥,陈宇鹏,等.益气温阳活血利水中药对充血性心力衰竭患者内皮素及一氧化氮的影响[J].中药新药与临床药理,2000,11(2)：71-73
[94]沈淑静,黄平东,黄衍寿,等.益气温阳活血利水法对心力衰竭兔模型神经内分泌的影响[J].中医研究,2006,19(12)：19-21
[95]Cooper KH. A mean of assessing maximal oxygen in2take[J]. JAMA,1968,203:135-138.
[96]McGavin C R, Gupta S P, McHardy G J R. Twelve-minute walking test for assessing disability in chronic bronchitis [J]. Br Med J,1976,1 (6013):822-823.
[97]Butland RJA, Pang J, Gross E R, etal. Two2, Six2, and 122 minute walking tests in respiratory disease [J].Br Med J,1982,284 (6329):1607-1608.
[98]Guyatt G H, Sullivan MJ, Thompson P J, et al. The 6-minutewalk:a new measure of exercise capacity in patients with chronic heart failure[J]. Can Med Assoc J,1985, 132 (8):919-923.
[99]Knox A J, Morrison JFJ, Muers M F. Reproducibility of walking test results in chronic obstructive airways disease [J].Thorax,1988,43(5):388-392.
[100]中华心血管病杂志编委会心血管药物对策专题组.心血管药物临床试验评价方法建议V.抗心力衰竭药[J].中华心血管病杂志,1998,26：405-413.
[101]Q uit tanM, W iesinger GF, Crevenna R, et al. Crosscultural adap tat ion of the Minneso ta Living w ith Heart Failure Q uest ionnaire fo r German2speak ing patients[J]. J RehabilM ed,2001,33:182-186.
[102]Cahalin L P, M ather MA, Sem igran MJ, et al. The six minute w alk test p redicts peak oxygen up take and survival in pat ients w ith advanced heart failure [J]. Chest, 1996,110:3252331.
[103]惠海鹏,许顶立,刘煜,等.6分钟步行实验在充血性心力衰竭患者中的应用价值[J].现代康复,2001,5：36-37.
[104]Bitter V, Weiner D H, Yusuf S, et al. Prediction of mortality and morbidity with a 62minute walk test in patients with left ventricular dysfunction [J]. JAMA,1993, 270 (14):1702-1707.
[105]Zugck C, Kruger C, Durr S, et al.Is the 62minute walk test are liable substitute for peak oxygen uptake in patients with dilated cardiomyopathy? [J]. Eur Heart J 2000,21(7):540-549.
[106]Opasich C, Pinna G D, Mazzaa A, et al. Reproducibility of the six minute walking test in chronic congestive heart failure patients:pracitical implications [J]. Am J Cardiol,1998,81(12):1497-1500.
[107]Lipkin D P. The role of exercise testing in chronic heart failure[J]. Br Heart J, 1987,58(6):559-566.
[108]Myers J, Walsh D, Buchanan N, et al. Can maximal cardiopulmonary capacity be recognized by plateau in oxygen up take? [J].Chest,1989,96(6):1312-1316.
[109]Riley M, McParland J, Stanford C F, et al. Oxygen consumption during corridor walk testing in chronic cardiac failure[J]. Eur Heart J,1992,13 (6):789-793.
[110]Canal in L P, Michaier M A, Semigran M J, et al. The six2 minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure [J]. Chest 1996,110(2):325-332.
[111]Morales F J, Martinez A, Mendez M, et al. A shuttle walk test for assessment of functional capacity in chronic heart failure [J].Am Heart J,1999,138 (2 Pt 1) 291-298.
[112]Bitter V. Determining prognosis in congestive heart failure:Role of the 62minute walk test [J]. Am Heart J,1999,138 (4 Pt 1):593-596.
[113]Lucas C, Stevenson L W, Johnson W, et al. The 62minute walk and peak oxygen consumption in advanced heart failure:aerobic capacity and survival [J]. Am Heart J,1999,138 (4 Pt 1):618-624.
[114]Zugck C, Kruger C, Durr S, et al. Is the 6-minute walk test are liable substitute for peak oxygen uptake in patients wi th dilated cardiomyopathy? [J].Eur Heart J,2000, 21(7):540-549.
[115]Shah M R,Hasselblad V, Gheorghiade M, et al. Prognostic usefulness of the six2minute walk in patients with advanced chronic heart failure secondary to ischemic or nonischemic cardiomyopathy [J].Am J Cardiol,2001,88 (9):987-993.
[116]Roul G, Germain P, Bareiss P, et al. Does the 62minute walk test predict the prognosis in patients with NYI1A class Ⅱ or Ⅲchronic heart failure [J]?Am Heart J 1998,136(3):449-457.
[117]Mungall 1 P F,Hainsworth R. Assessment of respiratory function in patients with chronic obstructive airways disease [J]. Thorax,1979,34(2):254-258.
[118]Demers C, McKelvie R S, Negassa A, et al. Reliability,validity, and responsiveness of the six2minute walk test in patients with heart failure[J]. Am Heart J,2001,142 (4):6982703.
[119]Lipkin D P, Scriven A J, Crake T, et al. Six minute walking test for assessing exercise capacity in chronic heart failure [J].BrMed J,1986,292(6521):653-655.
[120]Cahalin L P, Pappagianopoulos P, Prevost S, et al.The relationship of the 62min walk test to maximal oxygen consumption in transplant candidates with end2stage lung disease[J]. Chest,1995,108(2):452-459.
[121]王大英,范维琥.6分钟步行试验在慢性充血性心力衰竭中的应用[J].临床荟萃,2003,18(7)：412-413
[122]Conley K E, Esselman P C, Jubrias S A, et al. Aging, muscle properties and maximal 02 uptake rate in humans. J Physiol,2000,526:211-217.
[123]Forissier J F, Vernochet P, Bertrand P, et al. Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. Eur J Heart Fail,2001,3:335-342.
[124]Butland R J A, Pang J, Gross E R, et al. Two2, six2 and 122 minute walking test in respiratory disease. Br Med J,1982,284:1607-1608.
[125]Cahalin L P, Mathier M A, Semigran M J, et al. The six minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest,1996, 110:325-332.
[126]Faggiano P, D'Aloia A, Gualeni A, et al. Assessment of oxygen uptake during the six minute walk test in patients with heart failure. Preliminary experience using a portable device. Am Heart J,1997,134:203-206.
[127]姜虹,戴闺柱.心力衰竭患者心功能的评定—6分钟步行试验与运动峰耗氧量对比研究.临床心血管病杂志,1995,11(5)：270-272.
[128]唐艳芬,高想,蒋凤荣,等.利心冲剂对阿霉素所致慢性心力衰竭大鼠T I M P 21、T G F 2β的影响[J].上海中医药杂志,2009,43(10)：62-64
[129]李玉玲,杨建业,唐俊明,等.阿霉素诱导大鼠心衰模型不同方案的比较[J].中国比较医学杂志,2006,16(2)：93-96.
[130]芦玲巧,曾翔俊,郝刚.大鼠心力衰竭模型的构建与鉴定[J].中国比较医学杂志,2012,22(8)：22、25.
[131]褚春,杨军,谭芳,等.腹主动脉缩窄大鼠心力衰竭时心室肌细胞电生理失稳态及Ito的变化[J].医学信息：上旬刊,2010,23(17)：3107-3108.
[132]褚春,杨军,王苏燕,等.厄贝沙坦对心力衰竭大鼠心肌电生理失稳态和心室肌细胞I_(Ca-L)电流的影响[J].中南医学科学杂志,2012,40(1)：42-46.
[133]Heinke M Y, Wheeler C H, Yan J X, et al. Changes in myocardial protein expression in pacing-induced canine heart failure[J]. Electrophoresis,1999,20(10):2086-2093.
[134]Montgomery C, Hamilton N, Ianuzzo C D. Energy status of the rapidly paced canine myocardium in congestive heart failure[J]. J Appl Physiol,1992,73(6):2363-2367.
[135]Heinke M Y, Wheeler C H, Yan J X, et al. Changes in myocardial protein expression in pacing-induced canine heart failure[J]. Electrophoresis,1999,20(10):2086-2093.
[136]Kajstura J, Zhang X, Liu Y, et al. The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy[J]. Circulation,1995,92(8):2306-2317.
[137]邓青秀,彭成.中医药心力衰竭动物模型的研究现状[J].四川动物,2011,30(2)：296-300.
[138]周文武,林玲,陈军,等冠脉结扎法制做大鼠心肌缺血模型[J].中国实验动物学报,2004,12(4)：226—231
[139]朱文晖,张晓红,肖渊茗.超声心动图评价心力衰竭大鼠模型心功能改变[J].中南大学学报：医学版,2009,34(5)：453-456.
[142]Xie ZJ, Cail T. Na+ -K+ -ATPase-Mediated Signal Transduction:from protein interaction to cellular function [J]. Mol Interv,2003,3(3):157-168.
[143]Tuunanen H, Engblom E, Naum A, et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure [J]. Circulation, 2006,114(20):2130-2137.
[144]Halbirk M, Norrelund H, Moller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function [J]. Am J Physiol Heart Circ Physiol,2010,299 (4):H1220-1225.
[145]Abozguia K, Elliott P, McKenna W, et al.Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy [J]. Circulation,2010,122 (16):1562-1569.
[146]Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure [J].Herz,2002,27 (7):621-636.
[147]Bristow M. Etomoxir:a new approach to treatment of chronic heart failure [J]. Lancet, 2000,356 (9242):1621-1622.
[148]Holubarsch CJ, Rohrbach M, Karrasch M, et al. A doubleblind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure:the ERGO (etomoxir for the recovery of glucose oxidation) study [J]. Clin Sci (Lond),2007,113 (4):205-212.
[149]KANTOR P F, LUCIEN A, KOZAK R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid to glucose by inhibiting mitochondrial long-chain 3 ketoacyl conzyme A thiolase[J]. Circ Res,2000,86:580-586.
[150]Fragasso G, Palloshi A, Puccetti P, et al.A randomized clinical trial of trimetazidine, apartial free fatty acid oxidation inhibitor, in patients with heart failure [J].J Am Coll Cardiol,2006,48 (5):992-998.
[151]Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy [J].Circulation, 2008,118(12):1250-1258.
[152]El-Kady T, El-Sabban K, Gabaly M, et al.Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy:a24-month study [J]. Am J Cardiovasc Drugs,2005,5 (4):271-278.
[153]Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure [J].Circ Res,2002,91 (4):278-280.
[154]Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure [J].Am J Physiol Heart Circ Physiol,2008,295 (5):H2149-2155.
[155]Ferrari R, Merli E, Cicchitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases:a review [J].Ann N Y Acad Sci,2004,1033:79-91.
[156]Mingorance C, Rodriguez-Rodriguez R, Justo ML, et al. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders [J].Vasc Health Risk Manag,2011,7:169-176.
[157]Serati AR, Motamedi MR, Emami S, et al. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms [J]. Cardiology,2010,116(3):178-182.
[158]徐希奇,荆志成,蒋鑫,等.静脉注射左卡尼汀治疗肺动脉高压并右心功能障碍疗效观察[J].中华心血管病杂志,2010,38(2)：152-155
[159]黄俊.慢性心力衰竭诊断和治疗2012：现状和进步[J].心血管病学进展,2012,33(1)：1-5
[160]黄培红,靳利利,李典鸿,等.加味参附颗粒配合心脏康复疗法治疗慢性心衰临床观察[J].按摩与康复医学,2011,2(16)：19-20.
[161]苏慧,靳利利,李典鸿,等.加味参附颗粒改善慢性心力衰竭患者生存质量的临床研究[J].福建中医药,2011,42(5)：27-29.
[162]黄培红,靳利利,刘秋江,等.加味参附颗粒对慢性心力衰竭患者预后的影响[J].福建中医药,2011,42(5)：19-20.
[163]靳利利,刘秋江,李典鸿,等.加味参附颗粒对慢性心功能不全患者心功能及血浆脑钠肽的影响[J].广州中医药大学学报,2011,28(5)：468-470.
[164]卞继芳,丁达,吕娜,等.加味参附颗粒治疗缓慢性心律失常30例临床研究[J].国医论坛,2009,24(2)：21、22.
[165]卞继芳,丁达,王清海,等.加味参附颗粒治疗缓慢性心律失常的食道电生理研究[J].河南中医学院学报,2009,24(2)：34-35.
[166]袁丁,靳利利,李典鸿,等.加味参附颗粒治疗慢性心力衰竭疗效分析[J].吉林中医药,2011,31(7)：633-634.
[167]李典鸿,王清海,靳利利,等.加味参附颗粒治疗冠心病合并心功能不全疗效观察[J].实用中医内科杂志,2009(11).
[168]杨思华,王清海,李爱华,等.加味参附颗粒治疗顽固性心力衰竭的超声临床疗效评价[J].新中医,2004,36(5)：33-34.
[169]黄琳,王清海,李典鸿,等.加味参附颗粒治疗慢性肺心病心力衰竭46例临床观察[J].中国中医急症,2003,12(6)：507-508.
[170]李慧,李爱华,刘乡,等.加味参附颗粒治疗充血性心力衰竭及对甲状腺激素的影响[J].中国中医药信息杂志,2005,12(2)：14-15.
[171]江儒文,王清海.加味参附颗粒治疗充血性心力衰竭的研究进展[J].中华中医药学刊,2008,26(11)：2371-2372.
[172]黄琳,于清海,李典鸿,等.加味参附颗粒对慢性心力衰竭患者神经内分泌的影响[J].中华中医药学刊,2008,26(4)：791-792.
[173]李慧,王清海,李爱华,等.加味参附颗粒对充血性心力衰竭病人血流动力学的影响[J].中西医结合心脑血管病杂志,2005,3(2)：100-101.
[174]杨思华,王清海,陈宁,等.加味参附颗粒对顽固性心力衰竭病人心功能的影响[J].中西医结合心脑血管病杂志,2004,2(7)：383-384.
[175]祝世讷.阴阳的本质究竟是什么.山东中医学院学报,1996,(1)：2-6.
[176]杨武功,杨滨.中医阴阳的物理本质.中国中医基础医学杂志,1995,(3)：53-54.
[177]张永忠.论人的阴阳与代谢的关系.中国中医基础医学杂志,1999,5(11)：57-60
[178]Conley K E, Esselman P C, Jubrias S A, et al. Aging, muscle properties and maximal 02 uptake rate in humans. J Physiol,2000,526:211-217.
[179]褚春,杨军,谭芳,等.腹主动脉缩窄大鼠心力衰竭时心室肌细胞电生理失稳态及Ito的变化[J].医学信息：上旬刊,2010,23(17)：3107-3108.
[180]褚春,杨军,王苏燕,等.厄贝沙坦对心力衰竭大鼠心肌电生理火稳态和心室肌细胞I_(Ca-L)电流的影响[J].中南医学科学杂志,2012,40(1)：42-46.
[181]Fischer M, Baessler A, Hense H W, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample[J]. Eur Heart J,2003,24(4):320-328.
[182]Fragasso G, Palloshi A, Puccetti P, et al. A randomized cl inical trim of trimetazidine, a partial free fatty acids oxidation inhibitor。in patients wi th heart failure. J Am Coil Cardiol。2006,48:992-998.